Login
ZeroStack Corp. logo

ZeroStack Corp.

zerostack.ai

What Do They Do?

Invests in digital assets as an AI-focused treasury and asset manager, and distributes pharmaceutical products to international markets.

How Do They Make Money?

Pharmaceutical customers pay for products shipped or delivered, generally within 0 to 30 days and sometimes up to two months. The filing describes the company primarily as a pharmaceutical distributor.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical customers buy the products Phatebo distributes across international markets, primarily in Europe, with sales also in Asia, Latin America and North America.

Do Revenues Turn Into Profits?

No. It lost $119.7M in FY2025.

Operating income, FY2025
−433% of revenue
▼ −1633% (Loss) vs FY2024 (−$8.9M, −25%)
Net income, FY2025
−336% of revenue
▼ −653% (Loss) vs FY2024 (−$15.9M, −44%)
Free cash flow, FY2025
−25% of revenue
▼ −70% (Loss) vs FY2024 (−$5.2M, −14%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Revenue
▲ +41%
vs $9.7M in Q2 FY2025
Net income
▼ −921% (Loss)
vs −$2.4M in Q2 FY2025
  • Nov 5, 2026 Changed its independent accounting firm ZeroStack dismissed Davidson and appointed L J Soldinger to review its September quarter and audit its 2026 financial statements; Davidson said interim review procedures remained incomplete.
  • Nov 3, 2026 Agreed to sell Phatebo The proposed sale of all Phatebo shares for €2,150,000 is subject to German foreign investment clearance and other closing conditions.
  • Aug 19, 2026 Acquired MemeCore tokens in exchange for shares and warrants The completed transaction brought in MemeCore tokens valued at approximately $1 billion as of August 19, 2026.
  • Jul 20, 2026 Completed a private financing in 0G tokens Investors contributed 142,232,948 0G Tokens in exchange for shares, and ZeroStack acquired the tokens through its wholly owned subsidiary.

From cannabis to digital assets and AI The earlier report described a cannabis business spanning consumer brands, cultivation and distribution alongside pharmaceuticals. The latest report centers on a digital-asset treasury and AI strategy, while retaining pharmaceutical distribution and describing the sale of its legacy hemp and cannabis business.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support